Currently out of the existing stock ratings of Alex Schwartz, 11 are a BUY (84.62%), 2 are a HOLD (15.38%).

Alex Schwartz

Work Performance Price Targets & Ratings Chart

Analyst Alex Schwartz works with a stock forecast success ratio of 33.33% fulfilled within 14.5 days on average. Previously, Alex Schwartz worked at STIFEL.

Alex Schwartz’s has documented 24 price targets and ratings displayed on 4 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ANAB, AnaptysBio at 21-Feb-2024.

Wall Street Analyst Alex Schwartz

Analyst best performing recommendations are on MNTA (MOMENTA PHARMACEUTICALS).
The best stock recommendation documented was for MNTA (MOMENTA PHARMACEUTICALS) at 1/5/2018. The price target of $15 was fulfilled within 4 days with a profit of $2.55 (14.53%) receiving and performance score of 36.32.

Average potential price target upside

ESPR Esperion Therapeutics PBYI Puma Biotechnology MNTA Momenta Pharmaceuticals ANAB AnaptysBio

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

16

$12.97 (428.05%)

16

18 days ago

0/4 (0%)

$13.38 (510.69%)

Buy

8

$4.97 (164.03%)

8

18 days ago

0/6 (0%)

$5.38 (205.34%)

Buy

4

3 months 9 days ago

1/3 (33.33%)

$2.63 (191.97%)

6

Hold

9

4 months 23 days ago

4/8 (50%)

$2.84 (46.10%)

92

Hold

3

$-0.03 (-0.99%)

1 years 23 days ago

4/7 (57.14%)

$1.46 (94.81%)

80

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Alex Schwartz is most bullish on?

Potential upside of $29.33 has been obtained for ANAB (ANAPTYSBIO)

What Year was the first public recommendation made by Alex Schwartz?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?